Objective To explore the clinical efficacy of mosapride on functional dyspepsia patients overlapping constipation-predominant irritable bowel syndrome. Methods 60 functional dyspepsia ( FD) patients overlapping constipation-predominant irritable bowel syndrome were randomly given mosapride (5 mg,tid) or trimebutine maleate(0. 1 mg.tid) for 4 weeks. The clinical efficacy was analyzed at the end of clinical course and 2 weeks later. Results At the end of 4-week trails, the symptoms associated to FD,sueh as postprandial fullness,early satiety,and upper abdominal pain,in patients treated with mosapride were more sufficiently improved compared to those in patients treated with trimebutine maleate (P<0.05). However, no significant difference as to symptoms above-mentioned was found between 2 therapies 2 weeks later(P >0.05). Additionally , similar unobvious differences between 2 therapies were also detected both at the end of clinical trials and 2 weeks later regarding to the symptoms including bloating,stool property and stool frequency(P >0. 05) . Conclusion These findings suggest that mosapride is safe and sufficient for treating the unctional dyspepsia patients overlapping constipation-predominant irritable bowel syndrome.%目的 观察莫沙必利对便泌型肠易激综合征(IBS-C)重叠功能性消化不良(FD)的临床疗效.方法 将60例IBS-C重叠FD患者随机分为两组,治疗组给予莫沙必利5 mg tid,对照组给予马来酸曲美布汀0.1 g tid,两组疗程均为4周,比较两组疗效.结果 治疗4周时莫沙必利组与马来酸曲美布汀组相比,对于餐后胀满、早饱、上腹部疼痛等FD的症状改善,莫沙必利组更加明显(P＜0.05)；治疗结束后2周,两组相比无统计学差异(p＞0.05)；对于腹胀、大便性状、大便次数等IBS-C的症状,治疗4周和治疗结束后2周,两组症状改善均无统计学差异(P＞0.05).治疗结束后2周,两组治疗有效率无明显差异(P＞0.05). 结论 莫沙必利治疗IBS-C重叠FD安全有效.
展开▼
